Lilly bolts on cancer bispecifics with $1.6bn Merus alliance

Always a big player in oncology, Eli Lilly has fallen behind some of its rivals when it comes to cancer immunotherapy, but a new R&D alliance with Dutch biotech Merus is further evidenc

Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO

Novartis buys into bispecific antibodies with Xencor deal

Agreement could add to Novartis' immuno-oncology pipeline.